DE60209886D1 - Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen - Google Patents
Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungenInfo
- Publication number
- DE60209886D1 DE60209886D1 DE60209886T DE60209886T DE60209886D1 DE 60209886 D1 DE60209886 D1 DE 60209886D1 DE 60209886 T DE60209886 T DE 60209886T DE 60209886 T DE60209886 T DE 60209886T DE 60209886 D1 DE60209886 D1 DE 60209886D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- kinase inhibitors
- tie2 receptor
- receptor kinase
- angiogenic diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26286201P | 2001-01-19 | 2001-01-19 | |
US262862P | 2001-01-19 | ||
PCT/US2002/001474 WO2002060382A2 (en) | 2001-01-19 | 2002-01-18 | Novel compounds and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60209886D1 true DE60209886D1 (de) | 2006-05-11 |
DE60209886T2 DE60209886T2 (de) | 2006-10-26 |
Family
ID=22999379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60209886T Expired - Fee Related DE60209886T2 (de) | 2001-01-19 | 2002-01-18 | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US7005434B2 (de) |
EP (1) | EP1372648B1 (de) |
JP (1) | JP2004521118A (de) |
AT (1) | ATE320255T1 (de) |
AU (1) | AU2002251788A1 (de) |
DE (1) | DE60209886T2 (de) |
ES (1) | ES2259079T3 (de) |
WO (1) | WO2002060382A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
JP4977611B2 (ja) | 2004-09-24 | 2012-07-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 新規な種類の界面活性剤様物質 |
US20080119367A1 (en) * | 2004-12-17 | 2008-05-22 | Mayo Foundation For Medical Education And Research | Prognosis of Renal Cell Carcinoma |
CA2593718A1 (en) * | 2004-12-31 | 2007-05-31 | Gpc Biotech Ag | Napthyridine compounds as rock inhibitors |
EP1917245A1 (de) | 2005-08-21 | 2008-05-07 | Abbott GmbH & Co. KG | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
US20070049592A1 (en) * | 2005-08-22 | 2007-03-01 | Geuns-Meyer Stephanie D | Bis-aryl urea compounds and methods of use |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6025489A (en) | 1989-11-17 | 2000-02-15 | Schering Aktiengesellschaft | Tricyclic pteridinones and a process for their preparation |
AU711426B2 (en) * | 1994-11-14 | 1999-10-14 | Warner-Lambert Company | 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5945431A (en) * | 1996-03-15 | 1999-08-31 | Biochem Therapeutics Incorporated | Cytomegalovirus inhibiting compounds |
GB9605437D0 (en) | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
ATE286053T1 (de) * | 1997-08-20 | 2005-01-15 | Warner Lambert Co | Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung |
ATE249219T1 (de) | 1997-12-11 | 2003-09-15 | Iaf Biochem Int | Antivirale verbindungen |
ES2310039T3 (es) | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular. |
-
2002
- 2002-01-18 US US10/466,585 patent/US7005434B2/en not_active Expired - Fee Related
- 2002-01-18 DE DE60209886T patent/DE60209886T2/de not_active Expired - Fee Related
- 2002-01-18 ES ES02720814T patent/ES2259079T3/es not_active Expired - Lifetime
- 2002-01-18 WO PCT/US2002/001474 patent/WO2002060382A2/en active IP Right Grant
- 2002-01-18 JP JP2002560578A patent/JP2004521118A/ja active Pending
- 2002-01-18 EP EP02720814A patent/EP1372648B1/de not_active Expired - Lifetime
- 2002-01-18 AU AU2002251788A patent/AU2002251788A1/en not_active Abandoned
- 2002-01-18 AT AT02720814T patent/ATE320255T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2259079T3 (es) | 2006-09-16 |
WO2002060382A3 (en) | 2002-09-26 |
EP1372648B1 (de) | 2006-03-15 |
US7005434B2 (en) | 2006-02-28 |
JP2004521118A (ja) | 2004-07-15 |
EP1372648A4 (de) | 2004-09-01 |
DE60209886T2 (de) | 2006-10-26 |
ATE320255T1 (de) | 2006-04-15 |
EP1372648A2 (de) | 2004-01-02 |
US20040048888A1 (en) | 2004-03-11 |
AU2002251788A1 (en) | 2002-08-12 |
WO2002060382A2 (en) | 2002-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
ATE337780T1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
ATE466580T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
ATE267830T1 (de) | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
DE69837809D1 (de) | Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen | |
DE60141636D1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
DE60209886D1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
DE60119285D1 (de) | Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall | |
ATE345818T1 (de) | S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen. | |
DE60020970D1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |